Added to YB: 2025-08-19
Pitch date: 2025-08-16
ARWR [neutral]
Arrowhead Pharmaceuticals, Inc.
+241.9%
current return
Author Info
Steve Wagner provides in-depth analysis of my favorite individual companies. Sign up for the newsletter.
Company Info
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Market Cap
$5.7B
Pitch Price
$20.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-104.33
P/E
-36.25
EV/Sales
9.63
Sector
Biotechnology
Category
growth
From Rockets to Runways to Payment Rails — 7 Q2 Earnings in Focus - Arrowhead Pharmaceuticals, Inc.
ARWR (earnings update): NDA for plozasiran accepted (PDUFA Nov 18, 2025); 4 Phase 3 programs advancing; $100M milestone from Sarepta on ARO-DM1 with another $200M likely by year-end; $900M cash supports launch prep. Thesis: plozasiran approval + cardiometabolic pipeline expansion.
Read full article (1 min)